Date:7/31/2009

---- (unaudited) Cash and investments $76,040 $87,664 ======= ======= Working capital $73,753 $84,044 ======= ======= Total assets $76,866 $88,546 ======= ======= 4% Convertible subordinated notes due 2011 $14,142 $18,967 ======= ======= Total long-term liabilities $14,142 $18,967 ======= ======= Accumulated deficit $468,990 $462,793 ======== ======== Stockholders' equity $59,869 $65,465 ======= ======= * Reflects the retroactive application of FASB Staff Position EITF 03-06-1 which requires unvested share based payment awards that contain non-forfeitable rights to dividends or dividend equivalents be participating securities and included in the computation of earnings per share pursuant to the two-class method.

    Contacts:
    Sean Cassidy
    Vice President and Chief Financial Officer

    203 871-4400

'/>"/>

SOURCE CuraGen Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
2. CuraGen Reports Third Quarter 2008 Financial Results
3. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
4. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
5. CuraGen to Present at the BIO CEO & Investor Conference
6. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
7. CuraGen Corporation Receives Notification from NASDAQ
8. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
9. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
10. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
11. CuraGen Appoints Clinical Oncologist as VP of Medical Development